Evidence map›Paper›PMID 42455256›Full record

ArticleAdvances in therapy2026

Vutrisiran Health Care Resource Utilization, Costs, Discontinuation, and Mortality: A Real-World Claims Analysis.

Nicole K Bart, Daniel P Judge, Margarita Udall, Liana Hennum, Melissa Allison, Avinash Dash, Shradha Sanghi, Rakesh Ramesh, Richard Wright

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicole K BartSt Vincent's Health Australia and Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. nicole.bart@svha.org.au.ORCID http://orcid.org/0000-0002-3546-0758
Daniel P JudgeMedical University of South Carolina, Charleston, SC, USA.ORCID http://orcid.org/0000-0002-3407-0248
Margarita UdallBridgeBio Pharma, Inc., San Francisco, CA, USA.
Liana HennumBridgeBio Pharma, Inc., San Francisco, CA, USA.
Melissa AllisonDefinitive Healthcare, Framingham, MA, USA.
Avinash DashDefinitive Healthcare, Bengaluru, Karnataka, India.
Shradha SanghiDefinitive Healthcare, Bengaluru, Karnataka, India.
Rakesh RameshDefinitive Healthcare, Bengaluru, Karnataka, India.
Richard WrightCedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0004-3590-3274

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVutrisiran was approved by the US Food and Drug Administration for hereditary transthyretin amyloid polyneuropathy (ATTR-PN) in 2022 and for transthyretin amyloid cardiomyopathy in 2025. Real-world data on vutrisiran health care resource utilization (HCRU), costs, discontinuation, and mortality in the USA are limited.

methodsWe conducted a retrospective analysis of patients initiating vutrisiran from 2022 to 2024 (when only approved for hereditary ATTR-PN) using Optum's de-identified Clinformatics

resultsIn Optum

conclusionPatients treated with vutrisiran continued to experience significant HCRU and costs related to disease progression despite treatment. New therapies are needed to further reduce burden and costs.

Indexed as

ATTR-PNHCRUTransthyretinVutrisiran

Identifiers

PMID42455256

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.